Cost-Utility Analysis of a Six-Weeks Ganoderma Lucidum-Based Treatment for Women with Fibromyalgia: A Randomized Double-Blind, Active Placebo-Controlled Trial

Authors: Miguel A. Garcia-Gordillo, Daniel Collado-Mateo, Miguel A. Hernández-Mocholi, Francesco Pazzi, Narcis Gusi, Francisco J. Dominguez-Muñoz & Jose C. Adsuar

Journal: MYOPAIN

Study Design:

• Intervention: 6 g/day of micro-milled Ganoderma lucidum (GL) or Ceratonia Siliqua (active placebo)
• Participants: 26 women with fibromyalgia
• Duration: 6 weeks
• Outcome Measures:
  • Quality-adjusted life years (QALYs) using EQ-5D-5L
  • Fibromyalgia Impact Questionnaire (FIQ)

Summary: This study evaluated the cost-effectiveness of adding Ganoderma lucidum (GL) to standard care for women with fibromyalgia. The results showed that GL improved quality of life, as measured by QALYs, compared to the active placebo. The incremental cost-utility ratio (ICUR) was €1348.55/QALY, and the cost-utility acceptability curve showed a 90% probability that GL is a cost-effective treatment option. Although there were no significant differences between groups in the FIQ, participants in the GL group experienced improvements in usual activities, pain/discomfort, and anxiety/depression.